Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
Adicet Bio, Inc. (ACET)
Last adicet bio, inc. earnings: 5/3 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aceto.com/ir/index.html
Company Research
Source: Business Wire
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with systemic sclerosis (SSc).Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.About ADI-001ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases. ADI-001 has been granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), systemic lupus erythematosus (SLE) with extrarenal involvement and systemic sclerosis (SSc). The Company
Show less
Read more
Impact Snapshot
Event Time:
ACET
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACET alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACET alerts
High impacting Adicet Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ACET
News
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Adicet Bio (NASDAQ:ACET) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Adicet Bio (NASDAQ:ACET) had its price target raised by analysts at HC Wainwright from $4.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Adicet Bio (NASDAQ:ACET) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
ACET
Earnings
- 11/5/25 - Miss
ACET
Sec Filings
- 11/17/25 - Form DEF
- 11/5/25 - Form PRE
- 11/5/25 - Form 10-Q
- ACET's page on the SEC website